Gilead stock rated buy for thriving HIV biz, promising oncology pipeline, and long-term growth potential despite volatility.

Biotech giant Gilead Sciences, Inc. GILD has put up a steady performance in 2024 amid a volatile market. Its shares have gained 15.4% in a year against the industry’s decline of 10.8%. The stock has ...

Gilead Sciences’ seladelpar has been recommended by the European Medicines Agency’s human medicines committee to treat the rare liver disease primary biliary cholangitis (PBC). The Committee for ...

It was a busy week in the biotech sector with lots of regulatory and pipeline updates. Among bigwigs, Gilead Sciences, Inc. GILD and GSK plc GSK had a few regulatory updates. Recap of the Week’s Most ...

Recall that seladelpar's FDA approval for primary biliary cholangitis [PBC] was expected in August and would open a ~$3 billion PBC market up to Gilead. Let's see how things have played out since ...

Credit: Collagery/Shutterstock. Gilead Sciences has entered a strategic partnership with Terray Therapeutics for the discovery and development of small-molecule therapies across several targets. The ...

In other recent news, Gilead Sciences has received positive feedback from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for seladelpar, a treatment for ...

Details are thin on the ground, but we know Gilead is tapping into Terray’s so-called tNova platform, the startup’s generative AI. This platform is designed to improve the speed, cost and ...

-- Gilead and Terray Will Leverage Terray’s tNova Drug Discovery Platform to Identify Small Molecule Therapeutics Against Targets of Interest -- FOSTER CITY, Calif. & LOS ANGELES--(BUSINESS WIRE ...

Gilead Sciences, Inc. GILD announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) recommended approval of seladelpar.